Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Bioconjug Chem. 2021 Aug 20;32(9):1935–1946. doi: 10.1021/acs.bioconjchem.1c00326

Figure 4:

Figure 4:

Schematic overview of the use of guest-modified serum albumin aggregates, which following administration preferentially accumulate at sites of disease. Subsequently, a cyclodextrin-modified polymer was administered to enable multivalent in situ complexation and agent delivery to the site bearing these guest-modified albumin aggregates.